- On August 24, 2017
- cannabis legalization, cannabis medicine, cannabis research, CBD, CBD extract, CBD oil, FDA, legal marijuana, marijuana CBD, marijuana research
The U.S. Food and Drug (FDA) is asking for input from patients who have experience using Cannabidiol (CBD) to treat medical conditions.
CBD is a non-psychoactive compound found in cannabis that’s proven therapeutic for treating pain, seizures and epilepsy. The FDA is putting together a recommendation for the United Nations’ World Health Organization (WHO) regarding CBD and several other substances, including ketamine.
The feedback will help WHO determine international drug restrictions under the 1971 Convention on Psychotropic Substances. The treaty seeks to curb drug trafficking and abuse by restricting imports/exports, limiting use to scientific and medical settings, and compelling member nations to punish infractions of the treaty.
Here’s what the FDA had to say about CBD (emphasis added):
Cannabidiol (CBD) is one of the active cannabinoids identified in cannabis. CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy. In the United States, CBD-containing products are in human clinical testing in three therapeutic areas, but no such products are approved by FDA for marketing for medical purposes in the United States. CBD is a Schedule I controlled substance under the CSA. At the 37th (2015) meeting of the ECDD, the committee requested that the Secretariat prepare relevant documentation to conduct pre-reviews for several substances, including CBD.
Declaring CBD beneficial puts the FDA at odds with the Drug Enforcement Agency (DEA), which ruled CBD to have no medicinal value, categorizing it as a Schedule I drug.
The FDA is asking for “interested persons to submit comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of 17 drug substances.”
The deadline for public comment is September 13.
Want to submit your comments to the FDA? Click here to go the Regulations.gov web site and click on the blue “Comment Now!” button.
Looking to get involved in the cannabis business? Start with an awesome cannabis web design package from Colorado 420 websites!